Palo Alto, CA, United States of America

Daniel Robert Hostetter

This inventor holds 23 USPTO granted patents and 8 published patent applications and 6 EPO patents, primarily in Cleavable Antibodies. Top assignees: Cytomx Therapeutics, Inc., University of California. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Daniel Robert Hostetter. Retrieved from https://idiyas.com/inventor/daniel-robert-hostetter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 

% Patents Active = 95.7

 

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 132(Granted Patents)


Location History:

  • Palto Alto, CA (US) (2020)
  • Rocklin, CA (US) (2020 - 2023)
  • Palo Alto, CA (US) (2016 - 2024)

Company Filing History:


Years Active: 2016-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Matrix Metalloproteinase
Cleavable Moieties
Bispecific Antibodies
Anti-CD3 Antibodies
Activatable Antibodies
Matriptase
Urokinase-Type Plasminogen
Cancer Treatment
Serine Protease
Interleukin-6 Receptor
PDL1 Antibodies
Multispecific Antibodies
23 patents (USPTO):Explore Patents

Title: The Innovations and Contributions of Daniel Robert Hostetter

Introduction: Daniel Robert Hostetter, based in Palo Alto, CA, is a distinguished inventor known for his significant contributions to the field of biotechnology. With an impressive portfolio of 20 patents, Hostetter has made considerable strides in research, particularly in the area of polypeptides and their applications in therapeutic and diagnostic contexts.

Latest Patents: Among Hostetter's latest patents are innovative works related to cleavable moieties and their methods of use. One notable invention is the development of Matriptase and u-plasminogen activator substrates and other cleavable moieties. This invention focuses on polypeptides that feature a cleavable moiety serving as a substrate for proteases like matriptase and uPA. These advancements extend to activatable antibodies and larger molecules that utilize these substrates, providing a foundation for various therapeutic, diagnostic, and prophylactic uses.

Another important patent by Hostetter involves Matrix metalloproteinase substrates and other cleavable moieties. This invention similarly highlights polypeptides inclusive of a cleavable moiety that acts as a substrate for matrix metalloproteases (MMP). The implications of this technology are vast, introducing methodologies for therapeutic and diagnostic applications using these specific polypeptides.

Career Highlights: Throughout his career, Hostetter has contributed to significant research initiatives at esteemed institutions. He has worked with CytomX Therapeutics, Inc. and the University of California, both of which are known for their cutting-edge research and development in biotechnology. His role in these organizations has allowed him to push the boundaries of innovation in the field.

Collaborations: Collaboration is a hallmark of scientific advancement, and Hostetter has partnered with notable colleagues such as Olga Vasiljeva and Stephen James Moore. These collaborations have enriched his research and fostered a dynamic exchange of ideas, leading to successful innovations in the areas of enzymes and cleavable moieties.

Conclusion: Daniel Robert Hostetter exemplifies the innovative spirit of contemporary biotechnology through his extensive patent portfolio and collaborative efforts. His inventions, particularly concerning polypeptides and their therapeutic applications, demonstrate a commitment to advancing medical science and improving health outcomes. As he continues to explore new frontiers in research, Hostetter's contributions are sure to have a lasting impact in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…